middle.news
How Amplia’s Narmafotinib Is Shaping New Hope for Pancreatic Cancer Patients
9:11am on Wednesday 29th of October, 2025 AEDT
•
Healthcare
Read Story
How Amplia’s Narmafotinib Is Shaping New Hope for Pancreatic Cancer Patients
9:11am on Wednesday 29th of October, 2025 AEDT
Key Points
Narmafotinib shows 7.6 months median progression-free survival, outperforming chemotherapy alone
New trial combining narmafotinib with FOLFIRINOX chemotherapy begins dosing patients
US Patent Office grants key patent securing drug protection until at least 2040
A$27.5 million capital raise completed, funding operations through 2027
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Amplia Therapeutics (ASX:ATX)
OPEN ARTICLE